Flagship Pioneering, LLC Long-Term Concentrated

CIK: 0001400240 · Show all filings

Period: Q2 2018 (← Previous) (Next →)

Filing Date: Aug 7, 2018

Total Value ($000): $522,113 (100.0% shares, 0.0% debt)

Holdings (5)

— EVELO BIOSCIENCES INC 41.2%

Value ($000) $215,154 Shares 18,233,403 Est. Cost $11.80 Unrealized —

DNLI DENALI THERAPEUTICS INC 26.1%

Value ($000) $136,011 Shares 8,918,749 Est. Cost $17.97 Unrealized +4.8%

— SERES THERAPEUTICS INC 20.9%

Value ($000) $109,073 Shares 12,682,876 Est. Cost $12.29 Unrealized —

— SYROS PHARMACEUTICALS INC 6.3%

Value ($000) $32,717 Shares 3,204,437 Est. Cost $13.87 Unrealized —

QTRX QUANTERIX CORP 5.6%

Value ($000) $29,158 Shares 2,030,495 Est. Cost $19.52 Unrealized -11.3%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	EVELO BIOSCIENCES INC	18,233,403	$215,154	41.2%	$11.80	—	COM	299734103
DNLI	DENALI THERAPEUTICS INC	8,918,749	$136,011	26.1%	$17.97	+4.8%	COM	24823R105
—	SERES THERAPEUTICS INC	12,682,876	$109,073	20.9%	$12.29	—	COM	81750R102
—	SYROS PHARMACEUTICALS INC	3,204,437	$32,717	6.3%	$13.87	—	COM	87184Q107
QTRX	QUANTERIX CORP	2,030,495	$29,158	5.6%	$19.52	-11.3%	COM	74766Q101